Assessment Status |
Full HTA submission received from Applicant |
HTA ID |
22051 |
Drug |
Rimegepant |
Brand |
Vydura® |
Indication |
For the acute treatment of migraine with or without aura in adults; and for the preventive treatment of episodic migraine in adults who have at least four migraine attacks per month. |
Rapid review commissioned |
13/07/2022 |
Rapid review completed |
12/09/2022 |
Rapid review outcome |
A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of rimegepant (Vydura®) compared with the current standard of care. |
Full pharmacoeconomic assessment commissioned by HSE |
28/09/2022 |
Pre-submission consultation with Applicant |
10/11/2022 |
Full submission received from Applicant |
07/02/2023 |